KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Income from Continuing Operations: 2018-2025

Historic Income from Continuing Operations for Esperion Therapeutics (ESPR) over the last 7 years, with Sep 2025 value amounting to -$32.0 million.

  • Esperion Therapeutics' Income from Continuing Operations fell 2.90% to -$32.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$107.8 million, marking a year-over-year decrease of 160.12%. This contributed to the annual value of -$4.8 million for FY2024, which is 97.74% up from last year.
  • According to the latest figures from Q3 2025, Esperion Therapeutics' Income from Continuing Operations is -$32.0 million, which was down 139.04% from -$13.4 million recorded in Q2 2025.
  • Over the past 5 years, Esperion Therapeutics' Income from Continuing Operations peaked at $58.2 million during Q1 2024, and registered a low of -$90.9 million during Q1 2021.
  • Over the past 3 years, Esperion Therapeutics' median Income from Continuing Operations value was -$32.0 million (recorded in 2025), while the average stood at -$27.8 million.
  • In the last 5 years, Esperion Therapeutics' Income from Continuing Operations soared by 192.46% in 2024 and then slumped by 171.30% in 2025.
  • Over the past 5 years, Esperion Therapeutics' Income from Continuing Operations (Quarterly) stood at -$69.1 million in 2021, then increased by 17.69% to -$56.8 million in 2022, then dropped by 1.02% to -$57.4 million in 2023, then skyrocketed by 63.71% to -$20.8 million in 2024, then fell by 2.90% to -$32.0 million in 2025.
  • Its Income from Continuing Operations was -$32.0 million in Q3 2025, compared to -$13.4 million in Q2 2025 and -$41.5 million in Q1 2025.